Description: Both LDTI and IFRS 17 have introduced numerous new metrics with most companies having only crossed the finish line, just complying with what's needed for reporting due the complexity and large amounts of data required to simply comply. How do you leverage all the work you did to get proper business insights across the organization that tie back to these reporting metrics?

Description: At the conclusion of the first part, attendees will be able to describe sources of reserve redundancy for products under Principle Based Reserve (PBR) and products under Commissioners' Annuity Reserve Valuation Method (CARVM). Such products include Term Life, Whole Life, Universal Life, and Fixed Annuity with and without rider. We will also review sources of capital redundancy from the C-1 factor under Risk-Based Capital (RBC) and assets such as Unrated Asset Credit Fund can have high C-1 factor even if its risks are limited. At the conclusion of the second part, the attendees will learn about potential Reserve Relief reinsurance solutions. Such solutions can provide Reserve Relief for annuity and term life businesses, as well as potential innovative asset-side solutions. Asset managers can structure assets that the C-1 factor aligned with the corresponding risk.

Description: Hot Topics in Setting Pension Return Assumptions is the third in a series, following Mathematics of Pension Return Assumption and Inflation, focusing on Effects, Forecasts, and Role in Pension Valuations. What time horizon is more appropriate for Capital Market Assumption (CMA) forecasts: mid-term or long-term time horizon, or a blend of both? How do we map the asset classes of a plan's own investment policy to the asset classes of investment forecasters' CMAs? If we use asset-smoothing for valuation assets, should we use market-driven expected returns or smoothed/average versions of them?

Description: At the end of this session attendees will understand how their company's existing cash flow models can be leveraged to meet the new requirements for principle-based reserves under VM-22.

Description: The upcoming VM-22 standard promises significant changes for the non-VA life insurance industry, impacting regulatory compliance, risk management, and financial reporting. This presentation equips insurance companies to navigate this crucial transition. We'll delve into key considerations from capital, modeling, and hedging perspectives, providing actionable insights for optimizing your VM-22 implementation strategy.

Description: "New regulatory requirements demonstrate an increased focus on understanding the liquidity and behavioral risks of structured assets and the close association and interaction with liability lapse risk. In the US, Actuarial Guideline LIII (“AG53”) requires additional analysis & disclosure around the risks of structured, less liquid assets used to back insurance liabilities. In Bermuda, the implementation of Consultation Paper #2 includes several targeted requirements to capture lapse risk, asset behavioral risk, and liquidity risk in a more robust and dynamic way. These emerging requirements necessitate enhanced ALM modeling capabilities and a more holistic view of liquidity risk that incorporates both sides of the balance sheet. In this session, we will discuss these requirements, what companies are doing to fulfill them, and how their efforts feed into a broader improvement of the ALM function."

Description: "This session is designed to provide small companies with a understanding of the VM22 update and practical steps to ensure a smooth implementation. VM22, a critical update in the industry, introduces new features, compliance requirements, and operational changes that can significantly impact business processes. Attendees will gain insights into the key aspects of the update, its implications for small businesses, and actionable strategies to prepare for implementation. The session will also address common challenges faced by small companies and provide best practices to mitigate risks and leverage the update for improved efficiency and compliance. By the end of this session, participants will be able to: 1. Understand the VM22 Update: - Explain the key features and changes introduced in the VM22 update. - Identify the compliance requirements and deadlines associated with the update. 2. Assess Impact on Small Companies: - Evaluate how the VM22 update affects existing business processes, systems, and workflows for small companies. - Recognize the potential challenges and opportunities. 3. Prepare for Implementation: - Identify the resources, tools, and support needed for a successful transition. - Access support for resources"

Description: This session will explore the evolving landscape of accident and health valuation, with a special focus on GAAP Long Duration Targeted Improvements. Discussion will delve into the intricacies of change brought by GAAP LDTI for calculation of both Lifetime Future Policy Benefits (LFPB) and Deferred Acquisition Costs, as well as potential downstream impacts to other activities related to general GAAP and STAT reserving such as experience analysis, model system conversion, financial planning and analysis, and statutory margin analysis. Attendees should be able to connect accounting and financial reporting concepts under GAAP LDTI to opportunities for technology modernization, improved transparency of financial analytics, and important considerations unique to Accident and Health products.

Description: Both LDTI and IFRS 17 have introduced numerous new metrics with most companies having only crossed the finish line, just complying with what's needed for reporting due the complexity and large amounts of data required to simply comply. How do you leverage all the work you did to get proper business insights across the organization that tie back to these reporting metrics? This presentation covers a perspective of pain points faced in getting over the the hurdle in complying with LDTI and IFRS 17, upcoming hurdles, emerging KPIs, as well as how to best manage the data, technology, and processes to produce the analysis around these KPIs efficiently.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.